Data reported from this trial at the European Society For Medical Oncology Annual Meeting 2019 formed the basis for the US Food and Drug Administration (FDA) breakthrough designation that was granted for LOXO-292 in the treatment of RET fusion-positive NSCLC, RET fusion-positive thyroid cancer, and RET-mutant MTC. This evidence concerns the gene RET and non-small cell lung carcinoma.